Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 336355
This license is non-exclusive for the Licensed process applied to human gene therapy.
The Licensor grants an immediate, complete and free access to the Know-how.
Licensor has agreed to share with a joint Licensor exploitation rights of the inventions of these patent applications and now wishes to share its rights under this technology with a industrial partner.
Licensee has as its activity the domain of genome and anti-viral therapy, the production of genomically-modified organisms, with respect to offering services to third parties, the sale of molecular biology products and reagents, the development of new therapeutic strategies, alone or in cooperation with pharmaceutical laboratories.
IPSCIO Record ID: 344487
The Licensor has already granted exploitation rights under the Patents to Third Parties for the production of the enzyme I-SceI, the use of the plasmid pSCM525, and, internal research. Consequently, the term exclusive is understood for the purposes of the present agreement as the Licensor being prohibited from exploiting or having exploited or granting a license or exploitation rights under the Patents to a Third Party in the Field, other than those already granted.
The patent is titled Nucleotide sequence encoding the enzyme I-SceI and the uses thereof.
IPSCIO Record ID: 336350
The amendment 2 updates the field of use.
The patent is titled â€œprocÃ©dÃ© de remplacement spÃ©cifique dâ€™une copie dâ€™un gÃ¨ne present dans le genome receveur par lâ€™intÃ©gration dâ€™un gÃ¨ne different de celui oÃ¹ se fait lâ€™intÃ©grationâ€
The Amendment 2 clarifies
This exclusion does not apply in either of the following cases
– As part of the creation of test animals used as a research and medication screening and validation tool;
– As part of use combined with the PGN patents on the one hand and I-SceI and/or I-Spom I and/or Mulligan on the other hand, excluding applications for Erythropoietin (EPO).
Amendment 3 clarifies
The Field covers the field of homologous recombination applied to all genes other than those that code for Erythropoietin (EPO).